Latigo Biotherapeutics reported a net loss of $25.8 million for the quarter ended June 30, 2026, with R&D expenses at $21.2 million and G&A expenses rising to $4.6 million. The company completed an upsized IPO in August 2026, raising gross proceeds of $397.4 million, bringing total cash resources sufficient to fund operations into 2029. Clinical highlights include the publication of positive Phase 2 results for onzotrigine in acute pain in the New England Journal of Medicine and plans to initiate Phase 3 trials in bunionectomy patients later this year. Latigo also appointed Naomi Lowy, M.D., former FDA deputy director, as senior vice president of global regulatory affairs. Latigo Biotherapeutics is a clinical-stage biopharmaceutical company developing non-opioid pain medicines.

Latigo Biotherapeutics, Inc. completed its initial public offering on August 10, 2026, selling 19,200,000 shares of common stock at $18.00 per share. The transaction generated approximately $345.6 million in aggregate gross proceeds before deducting underwriting discounts and estimated offering expenses. Concurrently, the company filed an amended and restated certificate of incorporation and adopted amended and restated bylaws with the Secretary of State of Delaware to reflect its status as a public entity. Latigo Biotherapeutics operates in the biotechnology industry, focusing on the discovery and development of novel therapeutics.